In 2021, Sub-Saharan Africa accounted for nearly 95% of global malaria cases and faced significant pregnancy-related malaria risks, with 13.3 million pregnant women exposed. Chemoprevention with sulfadoxine-pyrimethamine (SP) is effective but unsuitable for some, such as HIV-positive women or those in their first trimester. To address these challenges and support SDG 3, Medicines for Malaria Venture (MMV) is developing a new pyronaridine-piperaquine combination, safe from the first trimester and compatible with HIV treatment. This report aims to assist MMV in understanding stakeholder interest and implementation challenges.